The pharmaceutical company Bristol-Myers Squibb (BMS) recently obtained approval in the American market for IXEMPRA, a semi-synthetic analog of epothilone B, for the treatment of patients with metastatic breast cancer resistant or refractory to anthracyclines, taxanes, and capecitabine.
The effective treatment of many forms of cancer continues to pose a major problem for medicine. Many tumours fail to respond to standard forms of chemotherapy or become resistant to the medication. Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, the Hannover Medical School (MHH) and Leibniz-Universität (LUH) in Hanover have now discovered a chemical mechanism with which a natural substance - argyrin - destroys tumours. Today, the researchers publish their findings in the renowned scientific journal "CancerCell".
A new discovery has been made in cancer research. Researchers from the Laboratoire des collisions atomiques et moléculaires (CNRS/Université Paris 11) and the Laboratoire Génotoxicologie et cycle cellulaire (CNRS/Institut Curie) were the first to show that it is possible to improve hadrontherapy's(1) targeting and destruction of tumor cells by loading the cells with heavy atoms like platinum. This new method enables both the treatment's effectiveness and the ions' ballistic effect to be improved without damaging healthy tissue.
University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.
Whether a painless, portable device that uses electrical current rather than X-ray to look for breast cancer could be an alternative to traditional mammograms is under study at the Medical College of Georgia.